AR 42

Drug Profile

AR 42

Alternative Names: AR-42; NSC-D736012; OSU-HDAC42

Latest Information Update: 15 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics; Celgene Corporation; Ohio State University Comprehensive Cancer Center; Virginia Commonwealth University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Deacetylase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningioma; Neurilemmoma; Neurofibromatosis 2
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia
  • Discontinued Bladder cancer; Chronic lymphocytic leukaemia; Lymphoma; Meningioma; Multiple myeloma; Neurilemmoma; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Dec 2017 Arno Therapeutics terminates its licence for AR 42 before December 2017
  • 22 Dec 2017 Discontinued - Phase-0 for Meningioma (Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top